Correvio is seeking development and commercialization partners for BRINAVESS® and AGGRASTAT® that are proven competent in garnering new approvals and have successfully launched new products. Correvio has entered into several development and distribution agreements for BRINAVESS® and AGGRASTAT® worldwide. Please see below for a summary of our global capabilities and current partnership interests.



Correvio deploys an active sales force (Key Account Managers) detailing our products to key hospital customers in the 5 Major EU markets (France, Germany, Italy, Spain, UK), Western Europe and Nordic regions. Correvio has built a scalable platform to develop and commercialize products across the EU region with functions including Regulatory and Medical Affairs, Clinical Development, Quality Control and Assurance, Manufacturing and Supply Chain, new and mature Product Commercialization, and Pricing and Reimbursement, all led by senior personnel with several years of relevant industry experience in big, medium, and small pharma/bio-pharma environments.
Correvio is also actively seeking to license or acquire late- or commercial stage assets to complement its existing acute-care, hospital-based portfolio. To this end, Correvio has entered into agreements with several in-licensing partnerships with leading pharmaceutical companies. Please refer to our Product Section for a full list of our products.

Contact Business Development

Please contact Business Development at bd@correvio.com to discuss potential business opportunities.

By following this link you will be leaving the correvio.com website. Please note that Correvio does not take responsibility for the content displayed on other websites: